Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.37 per share from revenue of $ 0.89 million.
Looking ahead, the full year loss are expected at $ 5.57 per share on the revenues of $ 11.91 million.
Previous Quarter Performance
Deciphera Pharmaceuticals, Inc. came out with loss for the first quarter of $ 1.36 per share, from the revenue of $ 0.06 million. The quarterly revenues compared with the same quarter last year. Street analysts expected Deciphera Pharmaceuticals, Inc. to report loss of $ 1.25 per share on revenue of $ 0.21 million for the first quarter. The bottom line results missed street analysts by $ 0.11 or 8.8 percent, at the same time, top line results fell short of analysts by $ 0.15 million or 71.43 percent.
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of DCPH was $ 49.46, representing a 148.79 % increase from the 52 week low of $ 19.88 and a 30.45 % decrease over the 52 week high of $ 71.11.
The company has a market capital of $ 2.76 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”DCPH” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Deciphera Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.deciphera.com
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The companys lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors.
